Table S1.

Details of the studies included in the safety evaluation

Length (weeks)	Patients (n)	Treatments	ClinicalTrials.gov reference	Reference
52	1732	Indacaterol 300 μg od	NCT00393458	3
		Indacaterol 600 μg od
		Placebo
		Formoterol 12 μg bid
26	1683	Indacaterol 150 μg od	NCT00463567	4a
		Indacaterol 300 μg od
		Placebo
		Open-label tiotropium 18 μg od
52	415	Indacaterol 150 μg od	NCT00677807	6a
		Indacaterol 300 μg od
		Placebo
26	1002	Indacaterol 150 μg od	NCT00567996	5
		Salmeterol 50 μg bid
		Placebo
12	416	Indacaterol 150 μg od	NCT00624286	2
		Placebo
12	1123	Indacaterol 150 μg od	NCT00821093	10
		Salmeterol 50 μg bid
12	1598	Indacaterol 150 μg od	NCT00900731	11
		Tiotropium 18 μg od
12	323	Indacaterol 75 μg od	NCT01072448	12
		Placebo
12	318	Indacaterol 75 μg od	NCT01068600	12
		Placebo
12	347	Indacaterol 150 μg od	NCT00794157	13
		Indacaterol 300 μg od
		Placebo
26	563	Indacaterol 150 μg od	NCT00792805	–
		Indacaterol 300 μg od
		Placebo

^aNote: Patients in core and extension studies were not double counted in safety evaluation.

Abbreviations: od, once daily; bid, twice daily; n, number.